Key result
Adding dual-biomarkers to the GRACE score fails to improve in-hospital mortality prediction.
Why the study?
To examine whether a combination of biomarkers, including N-BNP and hs-CRP, better predicts mortality than the GRACE score in AMI patients receiving PPCI.
Does the combination of biomarkers (N-BNP and hs-CRP) improve the prediction of in-hospital mortality beyond the GRACE score in all-comer patients with AMI undergoing primary PCI?
Observational (n=754)
No
Does the combination of biomarkers (N-BNP and hs-CRP) improve the prediction of in-hospital mortality beyond the GRACE score in all-comer patients with AMI undergoing primary PCI?
The GRACE score remains a superior predictor of in-hospital mortality compared to biomarkers like N-BNP and hs-CRP in all-comer AMI patients undergoing primary PCI, and adding these biomarkers does not improve its predictive accuracy.
Answers are grounded in this paper and cite their sources.
GRACE alone suffices for in-hospital AMI mortality prediction; leaves open incremental value of these biomarkers in other cohorts or endpoints.
Objective This study examined the ability of a combination of biomarkers, including N-terminal pro-B-type natriuretic peptide (N-BNP) and high-sensitivity C-reactive protein (hs-CRP), to better predict mortality than the Global Registry of Acute Coronary Events (GRACE) score in acute myocardial infarction (AMI) patients who received primary percutaneous coronary intervention (PPCI). Methods The in-hospital mortality in 754 all-comer patients with AMI who underwent successful PPCI over 8 years was examined. A receiver operating characteristic (ROC) analysis was performed to determine the in-hospital mortality in a single center. A logistic regression analysis was used to compare the predictive accuracy of the GRACE score and biomarkers. The incremental predictive value of those biomarkers beyond the GRACE score was also examined. Results The mean age was 66±13 years old, and 609 patients with ST-elevated AMI (80.8%) were included. The in-hospital mortality was 6.8%. The GRACE score (in-hospital survivor/non-survivor: 106±33/161±32; p<0.05,) and N-BNP (in-hospital survivor/non-survivor: 2,458±7,058/8,880±1,1331 pg/mL; p<0.05) were significantly lower in survivors than in non-survivors. The area under the ROC curve (AUC) of in-hospital mortality of the GRACE score was significantly higher than that of the dual-biomarker combination (0.868/0.720; p<0.05). The AUC of the combination of the GRACE score and dual-biomarkers was not significantly higher than that of the GRACE score alone (0.870/0.868; p=0.747). Conclusion The measurement of representative cardiovascular biomarkers did not provide any additional benefit for mortality prediction beyond the GRACE score in AMI patients who received PPCI.
No takes yet. Share an insight, caveat, or question.
Kawamura et al. (2022) conducted an observational in Acute myocardial infarction (n=754). Combination of GRACE score and dual-biomarkers (N-BNP and hs-CRP) vs. GRACE score alone was evaluated on In-hospital mortality prediction (AUC) (p=0.747). The combination of the GRACE score and dual-biomarkers did not improve in-hospital mortality prediction compared to the GRACE score alone.
Synapse has enriched 10 related papers. Consider them for comparative context: